AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26056183
Drug: Nab-paclitaxel (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (150 mg/m2)
Trial: 26056183
Drug: Ixabepilone (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixabepilone (16 mg/m2)
Trial: 16760927
Drug: Placebo augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo augmentation
Trial: 1867231
Drug: Cholesterol-lowering therapy
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering therapy
Trial: 15064002
Drug: Medication (stimulants)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (stimulants)
Trial: 10838323
Drug: Triphasic norgestimate/EE-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic norgestimate/EE-containing oral contraceptive (ORTHO TRI‐CYCLEN(R))
Trial: 7936332
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg/day (Group A)
Trial: 7936332
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg/day and hypocaloric diet (Group B)
Trial: 2678584
Drug: Serum PAI‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum PAI‐1 levels above 550 ng/ml
Trial: 2678584
Drug: Serum PAI‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum PAI‐1 levels below 550 ng/ml
Trial: 26304854
Drug: Concurrent radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiotherapy with S-1 plus cisplatin (CRSC)
Trial: 26304854
Drug: Concurrent radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiotherapy with cisplatin alone (CRC)
Trial: 20601207
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol 400 mcg
Trial: 20601207
Drug: Ipratropium 80
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium 80 mcg
Trial: 30951521
Drug: Octreotide-LAR (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide-LAR (20 mg, intramuscular injections every 28 days for 3 years)
Trial: 30951521
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% sodium chloride solution, intramuscular injections every 28 days for 3 years)
Trial: 20122366
Drug: quetiapine 300
RxNorm normalized name: quetiapine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quetiapine 300 mg/d
Trial: 20122366
Drug: quetiapine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quetiapine 600 mg/d
Trial: 20122369
Drug: lithium 600
RxNorm normalized name: lithium 600 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lithium 600 to 1800 mg/d
Trial: 2152752
Drug: alfa‐2b recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfa‐2b recombinant Interferon (3,000,000 i.m. three times a week for three months, repeated after three months) + surgery therapy
Trial: 2152752
Drug: alfa‐2b recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfa‐2b recombinant Interferon (3,000,000 i.m. three times a week for three months, repeated after three months) + chemotherapy
Trial: 2152752
Drug: surgery therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: surgery therapy
Trial: 6941699
Drug: Central nervous
RxNorm normalized name: CENTRAL NERVOUS SYSTEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central nervous system prophylaxis (cranial radiation and intrathecal chemotherapy)
Trial: 8579005
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (IT)
Trial: 2970203
Drug: Paroxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (30 mg daily)
Trial: 2880767
Drug: Pivampicillin 350
RxNorm normalized name: pivampicillin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin 350 mg
Trial: 2202709
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg
Trial: 28705547
Drug: Closed incision
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed incision negative pressure therapy (ciNPT)
Trial: 26461064
Drug: Nurse-led medicines'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led medicines' monitoring using the West Wales ADR Profile for Mental Health Medicines
Trial: 19819677
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (30 g/ethanol/d for 28 days)
Trial: 19819677
Drug: Gin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gin (30 g/ethanol/d for 28 days)
Trial: 19624858
Drug: Both intervention
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intervention groups (weekly group‐based exercises and a home program for twelve months)
Trial: 14751699
Drug: Active corticosteroid
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active corticosteroid inhaler (doubling the dose)
Trial: 14751699
Drug: Placebo corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo corticosteroid inhaler (no change in dose)
Trial: 11751734
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n=11)
Trial: 11751734
Drug: Double the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double the ACE inhibitor dose (n=11)
Trial: 8111223
Drug: Brofaromine (85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brofaromine (85 mg/day)
Trial: 8111223
Drug: Imipramine (87
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (87 mg/day)
Trial: 3024864
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (Tilade) 4 mg four times daily
Trial: 30587918
Drug: Generic irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic irbesartan 150 mg
Trial: 17932102
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy (FT)
Trial: 31749275
Drug: Liraglutide 0.6
RxNorm normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 0.6 mg subcutaneous on the evening before surgery and 1.2 mg after induction of anaesthesia
Trial: 30880176
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg glepaglutide
Trial: 30880176
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg glepaglutide
Trial: 28630086
Drug: Cognitive stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive stimulation therapy specifically adapted for Parkinson's‐related dementias (CST‐PD), involving 30 min sessions delivered at home by the study companion three times per week over 10 weeks.
Trial: 25224595
Drug: Oral cryotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cryotherapy (OC) only
Trial: 12921454
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery and relaxation therapy
Trial: 10763948
Drug: Standardized multicomponent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized multicomponent behavioral therapy plus standard medical treatment (SMBT)
Trial: 10763948
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment alone (SMT)
Trial: 6145368
Drug: Pancuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.1 mg/kg intravenously
Trial: 3730522
Drug: Free combination
RxNorm normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free combination
Trial: 3730522
Drug: Atenolol tablet
RxNorm normalized name: Atenolol Tablets
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol tablet
Trial: 3730522
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination ('Tenoret 50')
Trial: 3730522
Drug: Chlorthalidone tablet
RxNorm normalized name: Chlorthalidone Tablets
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone tablet
Trial: 30073285
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide (50% nitrous oxide and 50% oxygen inhaled for 40 minutes)
Trial: 30073285
Drug: Placebo (50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (50% nitrogen and 50% oxygen inhaled for 40 minutes)
Trial: 28392509
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (25-mg agomelatine)
Trial: 15497661
Drug: Test and
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test and Reference formulations
Trial: 23939841
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (passive decompression via open operative ports)
Trial: 18250271
Drug: KAI-9803 (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAI-9803 (1.25 mg)
Trial: 18250271
Drug: KAI-9803 (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAI-9803 (5.0 mg)
Trial: 16488388
Drug: Credible placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Credible placebo treatment (PLA)
Trial: 12741878
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance back extension exercise on a 45 degrees Roman chair once weekly for 12 weeks, one set of 8‐20 dynamic repetitions to volitional exhaustion using hand‐held metal plates for additional resistance
Trial: 10834689
Drug: Gabexate mesylate
RxNorm normalized name: mesylate
DrugBank: Gabexate (DB12831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesylate (2 mg/kg/hr)
Trial: 10834689
Drug: Saline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (2 mL/hr; control group)
Trial: 1352563
Drug: Naftopidil 25
RxNorm normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Naftopidil 25 mg
Trial: 1352563
Drug: Naftopidil 50
RxNorm normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Naftopidil 50 mg
Trial: 30568303
Drug: APVAC1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APVAC1 vaccine derived from unmutated antigens
Trial: 30568303
Drug: APVAC2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APVAC2 vaccine targeting neoepitopes
Trial: 29857876
Drug: Horticultural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horticultural therapy program (10 sessions, once weekly)
Trial: 27097076
Drug: A. dracunculus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A. dracunculus (1000 mg) before breakfast and dinner for 90 days
Trial: 20467301
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise prescription throughout the study
Trial: 20467301
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise prescription after completing cancer treatment
Trial: 7857350
Drug: Pidotimod (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod (800 mg orally, twice daily) plus antibiotic (amoxycillin plus clavulanic acid: 1 g twice daily)
Trial: 196167
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with 'strong' sleeping pills followed by 'weak' sleeping pills
Trial: 30145946
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg once daily for 45 days
Trial: 17535867
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy for 6 months
Trial: 15302778
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) treatment
Trial: 15302778
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of UFH (>5000 U, or up to 90 U/kg)
Trial: 15302778
Drug: UFH weight‐indexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFH weight‐indexed dose
Trial: 12670035
Drug: IVECG signal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVECG signal conducted from the guide wire (group G)
Trial: 12670035
Drug: Group G
RxNorm normalized name: Prostaglandin group G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group G (guide wire)
Trial: 8200218
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg mifepristone 12 hours before surgical procedure
Trial: 8200218
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg mifepristone 24 hours before surgical procedure
Trial: 29049072
Drug: SGB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGB with 5 mL of normal saline
Trial: 25594610
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate (0.1%) cream (BMVc)
Trial: 25594610
Drug: Tacrolimus (0.1%)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (0.1%) ointment (TACo)
Trial: 27958255
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance correlation with vitB12
Trial: 17437361
Drug: Tigecycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (100 mg IV initial dose then 50 mg IV every 12 h)
Trial: 28114928
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene orientation (OHO) + supragingival treatment + simulation of using photodynamic therapy (PDT)
Trial: 31769240
Drug: Basal Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal Insulin
Trial: 17070446
Drug: Basal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal and Prandial Insulin
Trial: 9200390
Drug: Streptokinase with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase with subcutaneously administered heparin
Trial: 9200390
Drug: Streptokinase with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase with intravenously administered heparin
Trial: 1410141
Drug: Ritanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (10 mg daily for 8 weeks, followed by 4 weeks of continuation)
Trial: 3933455
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid solution containing 15.6% branched-chain amino acids
Trial: 17192685
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion (control)
Trial: 30829275
Drug: Games and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Games and story therapy along with motivational intervention (Group B)
Trial: 11897925
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg telmisartan + 12.5 mg HCTZ
Trial: 17009837
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg telmisartan
Trial: 10360855
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion (10% arginine hydrochloride, 30 g over 15 min)
Trial: 21145848
Drug: Danoprevir 200
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir 200 mg q12 h
Trial: 21145848
Drug: Danoprevir 300
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir 300 mg q12 h (non-responders)
Trial: 19441869
Drug: Ceftaroline 600
RxNorm normalized name: ceftaroline 600 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftaroline 600 mg every 12 hours for 5-14 days
Trial: 24421289
Drug: Alcohol infusion
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol infusion (target BrAC = 0.06 g/dl)
Trial: 21915733
Drug: Cefotetan disodium
RxNorm normalized name: Cefotetan Disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan disodium 1.0 g
Trial: 12113323
Drug: Human synthetic
RxNorm normalized name: Calcitonin, human synthetic
DrugBank: Human calcitonin (DB06773)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human synthetic secretin, mean dose 3.4 clinical units, administered intravenously every 4th week, on three occasions.
Trial: 7788039
Drug: Gemfibrozil 1200
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 1200 mg daily (divided into two doses) for 12 months
Trial: 1971701
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg ipsapirone (IPS)
Trial: 3896659
Drug: Naproxen (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (250 mg)
Trial: 25637151
Drug: Benson's relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benson's relaxation technique (audiotape listened to twice a day for 20 minutes for 8 weeks)
Trial: 12097666
Drug: Soy milk
RxNorm normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy milk (500 mL twice daily)
Trial: 31017851
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment for target morpheme
Trial: 31017851
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment for target morpheme
Trial: 25406730
Drug: Albiglutide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide (30 mg/week)
Trial: 21255780
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg/day)
Trial: 16838651
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose IFNalpha therapy (HDI)
Trial: 16838651
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose IFNalpha therapy (LDI)
Trial: 16838651
Drug: IFNbeta in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta in combination with chemotherapy
Trial: 16838651
Drug: IFNbeta gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IFNbeta gene therapy
Trial: 11872106
Drug: Myofascial trigger-point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial trigger-point massage therapy
Trial: 10094253
Drug: Continued therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued therapy with barbiturates, phenytoin, and valproate
Trial: 9345394
Drug: Rebif (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebif (recombinant human interferon beta) administered subcutaneously at a dose of 8 million international units (MIU) once a week for 2 years
Trial: 7430545
Drug: Indomethacin collyrium
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin collyrium administered prior to surgery
Trial: 28007620
Drug: O2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O2 group (received oxygen at 3 L/min via nasal prongs for three postoperative nights)
Trial: 9755260
Drug: No cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cooling (control group; rectal temperature = 37.0 +/- 0.2 degreesC, n = 10)
Trial: 9755260
Drug: Minimal systemic
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal systemic cooling (rectal temperature = 36.3 +/- 0.2 degreesC, n = 6)